Ulensy Corn Callus and Wart Remover

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. Each tablet is imprinted with "XYZ" on one side and "123" on the opposite side. It contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, magnesium stearate, and sodium starch glycolate. The tablets are supplied in bottles containing 100 units.

Uses and Indications

This drug is indicated for the relief of discomfort and the facilitation of the removal of corns, calluses, plantar warts, common warts, and flat warts.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Unscrew the cap of the bottle. For first-time use, it is necessary to remove the seal at the bottle mouth using scissors. Prior to application, the affected area should be cleaned and dried thoroughly. The healthcare professional should instruct the patient to gently squeeze the bottle to apply the liquid evenly over the affected area, allowing it to dry into a film. This application should be performed twice, once in the morning and once in the evening, with a double application each time.

For conditions affecting the feet, it is advisable to recommend nighttime application to minimize friction and enhance penetration. The patient should continue this daily application for a duration of two weeks or until the skin is fully restored.

Contraindications

Use of this product is contraindicated in patients with a known allergy to the formulation, particularly when applied to damaged skin in the facial area or around the eyes. Contact with the eyes should be strictly avoided; in the event of accidental exposure, the eyes must be rinsed thoroughly with water.

Warnings and Precautions

For external use only; ingestion is strictly prohibited. In the event of accidental ingestion, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay.

Healthcare professionals should advise patients to avoid contact with the eyes. Should accidental contact occur, it is essential to rinse the eyes thoroughly with water and seek medical attention if irritation persists.

No specific laboratory tests are recommended for monitoring in relation to the use of this product. However, vigilance in observing the aforementioned precautions is crucial for ensuring patient safety.

Side Effects

Patients should be aware that the product is for external use only and should not be ingested. In the event of accidental contact with the eyes, it is crucial to rinse the eyes thoroughly with water to mitigate any potential irritation.

Additionally, patients who are pregnant, intending to become pregnant, or breastfeeding are advised to consult a healthcare professional before using the product. No specific adverse reactions or side effects have been reported in clinical trials or postmarketing experiences.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Ulensy Corn Callus and Wart Remover (corn callus and wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely, as the product must be kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients or those intending to become pregnant should consult their healthcare provider before using this medication. It is important for women of childbearing potential to discuss their pregnancy status and any plans for pregnancy with their doctor. Additionally, breastfeeding patients are advised to seek medical guidance regarding the use of this medication while nursing.

Lactation

Lactating mothers are advised to consult their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, healthcare professionals should consider the potential risks and benefits when prescribing this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of overdosage, it is crucial to note that the product is intended for external use only. Ingestion of the product should be strictly avoided, as it may lead to adverse effects.

Recommended Actions Healthcare professionals should ensure that patients are informed about the risks associated with ingestion. If ingestion occurs, immediate medical attention should be sought. It is advisable to contact a poison control center or seek emergency medical assistance to manage the situation effectively.

Potential Symptoms While specific symptoms of overdosage may not be detailed, the potential for adverse reactions increases with ingestion. Symptoms may vary based on the individual and the amount ingested, necessitating careful monitoring and assessment by healthcare providers.

Management Procedures Management of overdosage should focus on supportive care. Healthcare professionals should evaluate the patient's condition and provide symptomatic treatment as necessary. Continuous monitoring of vital signs and supportive measures may be required until the patient is stabilized.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Patients should be advised to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients not to use the product around the eyes or on the facial area if they have a known allergy to it or if their skin is damaged.

Healthcare providers should emphasize the necessity of avoiding contact with the eyes. In the event of accidental eye contact, patients should be instructed to rinse their eyes thoroughly with water. Additionally, patients should be reminded to avoid eye contact altogether.

Patients should also be encouraged to consult their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding to ensure the safe use of the product in these circumstances.

Storage and Handling

The product is supplied in a sealed condition and should be stored at room temperature. It is essential to maintain the integrity of the packaging to ensure optimal product quality.

Additional Clinical Information

The product is administered topically, with a recommended application of twice daily—once in the morning and once in the evening—using a double application each time. For conditions related to the feet, a nighttime application is advised to enhance penetration and reduce friction.

Clinicians should counsel patients to avoid contact with the eyes; in the event of accidental contact, patients should rinse their eyes thoroughly with water. If ingested, immediate medical assistance or contact with a Poison Control Center is necessary. Additionally, patients should consult a healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding.

Drug Information (PDF)

This file contains official product information for Ulensy Corn Callus and Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)